SouthernWorldwide.com – A recent comprehensive review by Cochrane has raised significant questions about the safety and effectiveness of Alzheimer’s drugs that target amyloid. However, these conclusions have been met with pushback from some experts and pharmaceutical companies.
These particular drugs, classified as monoclonal antibodies, are developed with the aim of reducing or eliminating amyloid-beta. This protein naturally occurs in the body and can form into sticky plaques within the brains of individuals suffering from Alzheimer’s disease.
The Cochrane review analyzed data from 17 clinical trials. These trials collectively involved 20,342 participants who were experiencing mild cognitive impairment or early-stage Alzheimer’s dementia. The findings were detailed in a press release.
While prior studies had suggested that amyloid-targeting drugs could help to slow the progression of the disease, the Cochrane review concluded that their impact on memory decline and the severity of dementia was either negligible or extremely minor.
“Unfortunately, the evidence suggests that these drugs make no meaningful difference to patients,” stated lead author Francesco Nonino, a neurologist and epidemiologist at the IRCCS Institute of Neurological Sciences of Bologna, Italy, in the release.
“There is now a convincing body of evidence converging on the conclusion that there is no clinically meaningful effect,” he continued. “While early trials showed results that were statistically significant, it is important to distinguish between this and clinical relevance. It is common for trials to find statistically significant results that do not translate into a meaningful clinical difference for patients.”
The researchers also identified potential safety concerns associated with these anti-amyloid drugs. These included an increased likelihood of swelling and bleeding in the brain.
Read more : Will Xi Release Lai?
In many instances, these brain changes were only detectable through scans and did not manifest as clear symptoms. However, the long-term consequences remain unknown due to inconsistent symptom reporting across the studies.
Based on these findings, the researchers concluded that simply reducing amyloid-beta levels is unlikely to yield significant clinical benefits. Although these drugs are effective at lowering amyloid levels in the brain, this reduction does not appear to translate into improved outcomes for patients.
The research team recommended that future investigations should focus on exploring alternative biological pathways involved in Alzheimer’s disease.
“I see Alzheimer’s patients in my clinic every week and I wish I had an effective treatment to offer them,” said senior author Edo Richard, professor of neurology at Radboud University Medical Centre, in the release. “Existing approved drugs offer some benefit for some patients, but there remains a high unmet need for more effective treatments.”
“Given the absence of correlation between amyloid removal and clinical benefit, we need to explore other pathways to help address this devastating disease.”
The Alzheimer’s Association has formally requested that Cochrane retract the analysis, branding it as “scientifically flawed.” They warned that it could lead to “misguided and potentially harmful conclusions.” The association also highlighted that the Cochrane analysis failed to incorporate the perspectives of patients.
Furthermore, the association pointed to real-world clinical data, which they assert shows amyloid-targeting monoclonal antibodies exhibiting efficacy and safety profiles very similar to those reported in phase 3 clinical trials. This includes “clinically meaningful slowing of disease progression/cognitive decline with modest side effects.”
“Real-world data, along with clinical trial results, should guide decision-making,” the group emphasized.
Lilly, the manufacturer of donanemab (Kisunla), concurred with the Alzheimer’s Association, stating that the Cochrane review is based on an “inherently flawed methodology.”
“Combining data on unsuccessful molecules with approved medicines artificially dilutes the observed benefit and produces class-level conclusions that do not reflect the evidence for any individual approved therapy.”
Lilly further noted that regulatory bodies globally have assessed donanemab’s clinical data “on its own merits,” which they consider the “appropriate standard for determining benefit and risk for patients.”
Eisai, the producer of the Alzheimer’s drug lecanemab (Leqembi), expressed similar reservations.
“Extensive long-term clinical data out to four years and real-world experience with tens of thousands of patients globally show that patients who receive lecanemab continue to benefit from treatment.”
The researchers involved in the Cochrane review acknowledged certain limitations within their study. These included the possibility that clinical benefits might vary across different patient subgroups and individual drugs. They also noted that the follow-up periods for some of the analyzed studies might have been too short to accurately assess long-term outcomes.
Additionally, there was variability among the trials concerning dosing strategies and the outcomes measured. The majority of the trials also concentrated on early-stage Alzheimer’s disease, which may not be representative of individuals with more advanced stages of the condition.
